ALFA FinderBSE filing, NSE: FISCHER. Summary written from the filing by ALFA Finder's alert engine.
Fischer Medical Ventures Ltd: key numbers
- Share price
- ₹24.87
- Market cap
- ₹1,723 Cr
- Revenue (annual)
- ₹308.6 Cr
- Net profit (annual)
- ₹31.02 Cr
- P/E (TTM)
- 57.8×Sector 28.4×
- Promoter holding
- 63.08%+0.93% QoQ
- FII holding
- 6.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fischer Medical Ventures Ltd
All →Fischer Medical Ventures Management Change
Fischer Medical Ventures appointed Mr. Chan Sing En as Independent Director of SG subsidiary FMV Global Innovations, effective 27 Oct 2026. No financial consideration involved.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures Ltd filed its quarterly shareholding pattern under Regulation 31. This routine disclosure presents the company's current ownership structure.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Ltd has issued a Postal Ballot Notice seeking shareholder approval for creating security on subsidiary assets and promoter share pledges for proposed NCD issuance.
Fischer Medical Ventures Board Meeting Outcome
Fischer Medical Ventures' board approved a postal ballot notice for RPT consent and borrowing limits, and appointed a scrutinizer. No material transaction or financial figure was decided at this meeting.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting via video conferencing on September 29, 2026, with the requisite quorum present.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures' subsidiaries declared dividends totaling ₹26.95 Crore. This update provides financial information regarding subsidiary cash flows to the exchange.
- Value
- ₹26.95 Cr
Other board meeting date announcements
All →Muzali Arts Board Meeting Date
Muzali Arts has given prior intimation of a board meeting on 14 November 2026 to consider unaudited Q2 and half-year results ended 30 September 2026. The trading window has been closed since 1 October 2026 until 48 hours after results are declared.
Arvaya Healthcare Board Meeting Date
Arvaya Healthcare Ltd intimated a board meeting on November 13, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window remains closed until 48 hours after results are declared.
Aspire & Innovative Advertising Board Meeting Date
Aspire & Innovative Advertising scheduled a November 14, 2026 board meeting to consider unaudited standalone results for the half year ended September 30, 2026. No results figures are attached yet.
SI Capital & Financial Services Board Meeting Date
S.I. Capital will hold a board meeting on 12 November 2026 to consider unaudited standalone quarterly results. This is a prior intimation for the meeting.
Axel Polymers Board Meeting Date
Axel Polymers will hold a board meeting on 13 November 2026 to consider unaudited half-year results. The trading window stays closed until 48 hours after results.
FlySBS Aviation Board Meeting Date
FlySBS Aviation has scheduled a board meeting for 11 November 2026 to consider unaudited half-yearly results for the period ended September 2026. The trading window is not closed.